501 related articles for article (PubMed ID: 23644232)
1. Mammalian target of rapamycin (mTOR) pathways in neurological diseases.
Wong M
Biomed J; 2013; 36(2):40-50. PubMed ID: 23644232
[TBL] [Abstract][Full Text] [Related]
2. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.
Wong M
Epilepsia; 2010 Jan; 51(1):27-36. PubMed ID: 19817806
[TBL] [Abstract][Full Text] [Related]
3. mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology.
Jeong A; Wong M
Curr Neurol Neurosci Rep; 2016 Dec; 16(12):102. PubMed ID: 27815691
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
5. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives.
Schubert-Bast S; Rosenow F; Klein KM; Reif PS; Kieslich M; Strzelczyk A
Epilepsy Behav; 2019 Feb; 91():94-98. PubMed ID: 29941212
[TBL] [Abstract][Full Text] [Related]
6. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin and tuberous sclerosis complex.
Wataya-Kaneda M
J Dermatol Sci; 2015 Aug; 79(2):93-100. PubMed ID: 26051878
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
9. Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis.
McMahon J; Huang X; Yang J; Komatsu M; Yue Z; Qian J; Zhu X; Huang Y
J Neurosci; 2012 Nov; 32(45):15704-14. PubMed ID: 23136410
[TBL] [Abstract][Full Text] [Related]
10. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.
Zhang B; McDaniel SS; Rensing NR; Wong M
PLoS One; 2013; 8(2):e57445. PubMed ID: 23437388
[TBL] [Abstract][Full Text] [Related]
11. mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model.
Polchi A; Magini A; Meo DD; Tancini B; Emiliani C
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772672
[TBL] [Abstract][Full Text] [Related]
12. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex.
Yang F; Yang L; Wataya-Kaneda M; Hasegawa J; Yoshimori T; Tanemura A; Tsuruta D; Katayama I
J Dermatol Sci; 2018 Feb; 89(2):155-164. PubMed ID: 29146131
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.
Franz DN; Capal JK
Orphanet J Rare Dis; 2017 Mar; 12(1):51. PubMed ID: 28288694
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations.
Wong M
Exp Neurol; 2013 Jun; 244():22-6. PubMed ID: 22015915
[TBL] [Abstract][Full Text] [Related]
16. Role of the mTOR signaling pathway in epilepsy.
Meng XF; Yu JT; Song JH; Chi S; Tan L
J Neurol Sci; 2013 Sep; 332(1-2):4-15. PubMed ID: 23773767
[TBL] [Abstract][Full Text] [Related]
17. Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy.
Ryther RC; Wong M
Curr Neurol Neurosci Rep; 2012 Aug; 12(4):410-8. PubMed ID: 22544534
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.
McDaniel SS; Wong M
Neurosci Lett; 2011 Jun; 497(3):231-9. PubMed ID: 21354266
[TBL] [Abstract][Full Text] [Related]
19. Restoration of Normal Cerebral Oxygen Consumption with Rapamycin Treatment in a Rat Model of Autism-Tuberous Sclerosis.
Chi OZ; Wu CC; Liu X; Rah KH; Jacinto E; Weiss HR
Neuromolecular Med; 2015 Sep; 17(3):305-13. PubMed ID: 26048361
[TBL] [Abstract][Full Text] [Related]
20. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
Rensing N; Han L; Wong M
Epilepsia; 2015 Jul; 56(7):1088-97. PubMed ID: 26122303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
